Clinical study of blood-activating and stasis-resolving therapy (活血化瘀法) for patients with acute hypertensive cerebral hemorrhage small and moderate in amount and its influence on patients′ daily life ability
- VernacularTitle:早期使用活血化瘀法治疗对中小量高血压脑出血患者日常生活能力的影响
- Author:
Jiexia LI
;
Jianping MI
;
Shuqiu ZHAO
;
Rixiang HUANG
;
Haoji HUANG
;
Li LI
- Publication Type:Journal Article
- Keywords:
cerebral hemorrhage;
hypertension;
blood-activating and stasis-resolving therapy;
traditional Chinese medical therapy;
Danshen injection
- From:
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2006;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe blood-activating and stasis-resolving therapy (活血化瘀法)for patients with acute hypertensive cerebral hemorrhage small and moderate in amount and its influence on patients daily ability. Methods: One hundred and twenty-four cases were randomly divided into 3 groups: A group (n=52 cases), B group (n=34) and C group (n=38). Besides conventional therapies, A and B groups were treated additionally with 20 ml of Danshen injection (丹参注射液) in 5% glucose solution 250 ml for intravenous drip (once a day), 28 days constituting one therapeutic course, the beginning of the injection in A group was 24-48 hours after the attack and that of B group, 1 week after the attack. All the cases were evaluated by effective rate, neural defect score (NDS), ability of daily life (ADL), modified Barthel index (MBI), the duration for the absorption of intracranial hematoma, mortality, etc. The therapeutic effects of the 3 groups were compared after the treatment for 28 days, 3 months and 6 months. Results: The total significant effective rates in A group and B group were significantly better than that of C group (all P0.05). Conclusion: The early use of blood-activating and stasis-resolving therapy is effective for patients with acute hypertensive cerebral hemorrhage small and moderate in amount, it may promote the absorption of the intracranial hematoma, and improve the patients′ remote prognosis.
